PrognosDx Health

PrognosDx Health develops and commercializes epigenetic tests based on histone modification patterns.

PrognosDx Health, Inc., a biotechnology company, develops and commercializes epigenetic tests based on histone modification patterns. The company also provides services, such as pharmaceutical research-clinical sample analysis, clinical patient sample analysis tests for other cancers, and prostate cancer patient prognosis test. Its products are used in the development of cancer prognostic assays, therapeutic response prediction assays, and research tools and reagents. The company’s tissue-based global cellular histone biomarkers are prognostic for various cancers, such as prostate, pancreatic, breast, bladder, kidney, gastrics, colon, and lung cancer. PrognosDx Health, Inc. was incorporated in 2008 and is based in Palo Alto, California.